纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | SLC35D3 |
Uniprot No | Q5M8T2 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-416 aa |
活性数据 | MRQLCRGRVLGISVAIAHGVFSGSLNILLKFLISRYQFSFLTLVQCLTSSTAALSLELLRRLGLIAVPPFGLSLARSFAGVAVLSTLQSSLTLWSLRGLSLPMYVVFKRCLPLVTMLIGVLVLKNGAPSPGVLAAVLITTCGAALAGAGDLTGDPIGYVTGVLAVLVHAAYLVLIQKASADTEHGPLTAQYVIAVSATPLLVICSFASTDSIHAWTFPGWKDPAMVCIFVACILIGCAMNFTTLHCTYINSAVTTSFVGVVKSIATITVGMVAFSDVEPTSLFIAGVVVNTLGSIIYCVAKFMETRKQSNYEDLEAQPRGEEAQLSGDQLPFVMEELPGEGGNGRSEGGEAAGGPAQESRQEVRGSPRGVPLVAGSSEEGSRRSLKDAYLEVWRLVRGTRYMKKDYLIENEELPSP |
分子量 | 70.6 kDa |
蛋白标签 | GST-tag at N-terminal |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC35D3蛋白的假设性参考文献示例(因实际文献可能有限,以下内容基于相关领域研究推断):
---
1. **文献名称**: *"SLC35D3 mediates UDP-glucuronic acid transport in lysosomal glycosaminoglycan biosynthesis"*
**作者**: Zhang Y, et al.
**摘要**: 本研究解析了SLC35D3作为UDP-葡萄糖醛酸转运蛋白的功能,证明其通过介导溶酶体内糖胺聚糖(GAG)的生物合成,调控细胞代谢。重组人SLC35D3蛋白的体外实验证实了其底物特异性及pH依赖性转运活性。
2. **文献名称**: *"A loss-of-function mutation in SLC35D3 causes metabolic syndrome via impaired lipid trafficking"*
**作者**: Chen L, et al.
**摘要**: 通过基因敲除小鼠模型发现,SLC35D3缺失导致溶酶体脂质运输异常,引发胰岛素抵抗和肥胖。重组蛋白表达实验表明其通过结合固醇类分子参与脂质代谢通路。
3. **文献名称**: *"Structural insights into the human SLC35D3 transporter by cryo-EM"*
**作者**: Wang H, et al.
**摘要**: 利用冷冻电镜技术首次解析了重组人SLC35D3蛋白的三维结构,揭示了其底物结合口袋的关键氨基酸残基,为设计针对SLC35D3相关疾病的靶向药物提供了结构基础。
4. **文献名称**: *"SLC35D3 promotes hepatocellular carcinoma progression via modulating vesicular trafficking"*
**作者**: Liu X, et al.
**摘要**: 发现SLC35D3在肝癌组织中高表达,并通过调控囊泡运输促进肿瘤细胞侵袭。利用重组蛋白技术证实其与Rab GTPase蛋白互作,影响下游信号通路。
---
注:上述文献为假设性示例,实际研究中建议通过PubMed或Web of Science以“SLC35D3”为关键词检索最新成果。若需真实文献,可提供具体研究方向进一步筛选。
Solute Carrier Family 35 Member D3 (SLC35D3) is a nucleotide sugar transporter protein belonging to the SLC35 family, which facilitates the translocation of activated sugar moieties across intracellular membranes, predominantly in the Golgi apparatus and endoplasmic reticulum. This transport is critical for glycosylation processes, essential for post-translational modification of proteins and lipids, impacting cell-cell communication, receptor signaling, and extracellular matrix assembly. SLC35D3 specifically mediates the uptake of uridine diphosphate (UDP)-linked sugars, such as UDP-galactose or UDP-N-acetylglucosamine, into organelles to support glycan synthesis. Dysregulation of SLC35D3 has been linked to metabolic and developmental disorders, with studies suggesting its role in glucose metabolism, adipose tissue function, and dopamine receptor trafficking. Notably, mutations or altered expression of SLC35D3 are associated with obesity-related traits in murine models and potentially in human metabolic syndromes. Recombinant human SLC35D3. produced via heterologous expression systems (e.g., HEK293 or insect cells), retains structural and functional integrity, enabling in vitro studies to elucidate its transporter kinetics, interactome, and disease mechanisms. Its recombinant form is also explored as a therapeutic target for metabolic diseases or neurodegenerative conditions linked to glycosylation defects. Research remains ongoing to clarify its tissue-specific roles and regulatory networks in physiology and pathology.
×